Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Salivary Gland Neoplasms × RC48 antibody × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 3 pembrolizumab 2 Erlotinib Hydrochloride 2 Docetaxel 2 Carboplatin 2 spartalizumab 1 ixabepilone 1 entrectinib 1 Vorinostat 1 Tablets 1 Radiotherapy 1 RC48 antibody 1 Paclitaxel 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FPP(RGD)2 1 Everolimus 1 Epirubicin 1 Combined Modality Therapy 1 Chemoprevention 1 Cetuximab 1 Capecitabine 1 Bevacizumab 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Peking Union Medical College

Phase 1/2 Not yet recruiting

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡